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Abstract 
Pancreatic β-cells located within the islets of Langerhans play a central role in metabolic control. The 
main function of these cells is to produce and secrete insulin in response to a rise in circulating levels 
of glucose and other nutrients. The release of insufficient insulin to cover the organism needs results 
in chronic hyperglycemia and diabetes development. β-cells insure a highly specialized task and to 
efficiently accomplish their function they need to express a specific set of genes. MicroRNAs (miRNAs) 
are small non-coding RNAs and key regulators of gene expression. Indeed, by partially pairing to 
specific sequences in the 3’ untranslated regions of target mRNAs, each of them can control the 
translation of hundreds of transcripts. In this review, we focus on few key miRNAs controlling islet 
function and discuss: their differential expression in Type 2 diabetes (T2D), their regulation by genetic 
and environmental factors, and their therapeutic potential. Genetic and epigenetic changes or 
prolonged exposure to hyperglycemia and/or hyperlipidemia can affect the β-cell miRNA expression 
profile, resulting in impaired β-cell function and survival leading to the development of T2D. 
Experimental approaches permitting to correct the level of mis-expressed miRNAs have been shown 
to prevent or treat T2D in animal models, suggesting that these small RNAs may become interesting 
therapeutic targets. However, translation of these experimental findings to the clinics will necessitate 
the development of innovative strategies allowing safe and specific delivery of compounds modulating 
the level of the relevant miRNAs to the β-cells.  
 
Introduction 
More than ten years have passed since the first publications about the identification of abundant islet 
microRNAs (miRNAs) [1, 2]. Since then, we have learned much regarding the role played by miRNAs in 
the post-transcriptional regulation of islet cells (See e.g [3-5]).  During the last decades, it also became 
increasingly clear that failure of insulin-secreting β-cells plays an important role in the development of 
Type 2 diabetes (T2D; [6]).  The β-cell is the main cell-type present in the islet of Langerhans and release 
insulin in response to the increase in blood glucose levels occurring after a meal [7].  T2D is associated 
with both insulin resistance and impaired insulin secretion. Insulin resistance in peripheral tissues puts 
an extra demand to the β-cells and forces them to release more insulin. Moreover, prolonged exposure 
to elevated levels of lipids and glucose, a condition very often occurring in obese and insulin resistant 
individuals, perturbs the function of the β-cells and decrease their survival [8, 9]. Indeed, defective 
insulin secretion in T2D is associated with both reduced β-cell mass and impaired β-cell function. 
MiRNAs have been proven to affect both these processes [3-5].  
MiRNAs are small non-coding RNAs (21-23 nt) involved in post-transcriptional regulation of gene 
expression. Each miRNA contains a 6-8 nt long sequence in the 5’-end called the seed sequence that is 
important for recognition of the target mRNA.    The partial pairing of the seed sequence of each miRNA 
with the 3´untranslated regions (3’UTRs), and to some extent the 5´UTR, of target mRNAs reduces the 
expression of hundreds of transcripts. Target expression is repressed through translational inhibition 
and/or mRNA destabilization [10].   The miRNA genes are located within protein-coding genes or are 
produced from non-coding transcription units in intergenic regions.  In most cases, miRNA genes are 
transcribed in the nucleus by polymerase II into pri-miRNAs either together with their host gene or 
through the use of their own promoter (for detailed review on miRNA biogenesis see [10]). In some 
cases, several miRNAs form “clusters” and are produced from a single long transcript [11].  MiRNAs 
from the same cluster are not necessarily belonging to the same family.   Indeed, a family of miRNAs 
includes all miRNAs that share the same seed sequence, regardless of location in the genome  [12].  
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The microprocessor complex containing the DNA-binding protein DGCR8 and the RNase III Drosha[13]  
recognizes the unique hairpin structure of the pri-miRNAs, which is cleaved to produce the pre-miRNA.  
Exportin-5 enables the transport of the pre-miRNA out from the nucleus [14].  After exiting the nucleus, 
the RNase III enzyme Dicer processes the pre-miRNAs to generate mature miRNA duplexes.  
Knockdown of Dicer specifically in β-cells leads to diabetes development [15], showing the importance 
of miRNAs for β-cell function.   The miRNA duplex is then loaded into an Argonaute protein, initiating 
the formation of the mature silencing complex  that will finally contain only one strand (guide strand) 
of the miRNA duplex while the other (passenger strand) is usually degraded. Once loaded into the 
silencing complex, the seed sequence of the mature miRNA pairs with the corresponding sites within 
the target mRNA  and represses its translation [10].   Besides seed-dependent recognition of target 
mRNAs, recent studies [16, 17] have suggested the presence of seed-independent targeting of protein-
coding sequences (CDS).  This class of miRNA recognition elements in the CDS-region pairs with the 3’-
end of the miRNA (instead of the 5′ seed) to regulate translation. 
The posttranscriptional regulation of gene expression by miRNAs is complex.  Often the repression 
exerted on a specific gene by a single miRNA is modest. However, since full complementarity of the 
miRNA with the target sequence is not required, each miRNA can control the output of many target 
genes and each mRNA is often regulated by several miRNAs [12]. The role of miRNAs is to complement 
and extend the regulatory mechanisms exerted at transcription and by other nuclear events. Thus, the 
miRNA-mRNA interaction provides an extra layer of post-transcriptional gene regulation. Hence, 
miRNAs can modify and fine tune the expression of many different cellular pathways, and events 
interfering with miRNA action may lead to the development of a variety of diseases, including T2D [5, 
18].  
  
miRNAs in islet cells 
MiRNA expression analyses have identified miR-375 as one of the most abundant miRNAs in islet cells 
[19, 20].   Data from sorted human islet cells suggest that miR-375 is equally expressed in glucagon-
secreting α-cells as in the insulin-secreting β-cells [21], however changes in the level of this miRNA by 
overexpression or knockdown seem to mostly affect the β-cell [2, 22].  The expression of genes 
regulated by miR-375 are involved in multiple biological pathways within the β-cell.  These include β-
cell proliferation and differentiation, transcription factor regulation, insulin biosynthesis, insulin 
granule exocytosis and modulation of ion channels [22]. The expression level of miR-375 is relatively 
stable, and the miRNA has been used as endogenous control in at least one study [23].    The levels of 
miR-375 are not differentially-expressed in islets from human T2D individuals as compared to non-
diabetic (ND) controls [24, 25] and there are little changes in blood/serum miR-375 in T2D [26].  This 
is most likely explained by the high abundance and stability of miR-375 in islets and the broad target 
network influencing many functions. In view of the abundance of miR-375 in β-cells this miRNA has 
been proposed as a biomarker of β-cell loss in Type 1 diabetes [27]. However, the analysis of sera from 
newly diagnosed T1D patients led to contradictory results [28, 29].  
Other highly abundant miRNAs in islet cells are miR-29a and miR-29b. These miRNAs cause constitutive 
repression of a monocarboxylase transporter (MCT-1; SLC16A1)[23].  MCT-1 is one of the 
“disallowed/forbidden” proteins in the β-cells and its inhibition ensures that only glucose-derived 
rather than exogenous pyruvate is metabolized by the mitochondria. Suppression of MCT-1 prevents 
muscle-derived pyruvate from stimulating insulin release during exercise [30].  
Also, miR-200 family and miR-7 are highly expressed in islet cells. Members of the miR-200 family were 
demonstrated to influence β-cell survival and ablation of several of them in mice protects β-cells 
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against apoptosis [31]. Studies in mice revealed that miR-7a regulates β-cell function by targeting 
genes controlling insulin granule exocytosis [32].  MiR-9, one of the first detected islet miRNAs, also 
regulates exocytosis of insulin granules. Here increased levels of the miRNA repress the transcription 
factor Onecut-2 and increase the expression of granuphilin [1], a negative regulator of insulin 
exocytosis. 
Many miRNAs influence the process of insulin gene transcription and insulin biosynthesis.  Knock-down 
of a set of miRNAs, including miR-24, miR-26, miR-182, and miR-148 in isolated islets and cultured β-
cells reduced insulin promoter activity and, consequently, insulin content [33].  As mentioned above, 
the islet abundant miR-375 was also reported to influence insulin production through 3-
phosphoinositide dependent protein kinase-1 (Pdpk1) [34, 35], although the published data are 
contradictory. However, this discrepancy may be explained by the different dosage and cell-types used 
in the experiments.  In another study, miR-204 was demonstrated to regulate the expression of MafA 
[36], a key transcription factor controlling insulin expression.  MafA expression is also indirectly 
influenced by miR-132 and overexpression of this miRNA in rat islets increases the level of this 
transcription factor [37]. 
In all, miRNAs are involved in a variety of processes in the β-cell.  They regulate pathways important 
for development, proliferation and differentiation and other processes forming the β-cell identity.  
MiRNAs also control many key β-cell functions including insulin production, transport and exocytosis 
of insulin granules, cellular metabolism and the expression of specific ion-channels.  Thus, all these 
processes can be affected by changes in miRNA expression.   
Genetic and epigenetic regulation of miRNAs 
The pri-miRNAs are transcribed together with the host-gene or through their own promoter. There are 
relatively few studies that have investigated the transcriptional regulation of miRNAs in islet cells. Two 
regulatory elements have been described nearby the miR-375 precursor gene located in an intergenic 
region on chromosome 2 [38]. The first domain relates to the proximal promoter, whereas the second 
may correspond to a distal enhancer.  Keller et al. further showed that the transcription factor NeuroD1 
cooperates with Pdx1 to regulate the transcription of miR-375 [38]. The two miRNAs miR-132 and miR-
212 are generated from the same transcript and form a miRNA cluster.  These two miRNAs share also 
the same seed sequence and thus belong to the same family. In humans, the gene transcribing the 
miR-132/miR-212 cluster is located in an intergenic region on chromosome 17p13.3.  Transcriptional 
regulation of this miRNA cluster in β-cells includes the novel transcription factor Calmodulin Binding 
Transcription Activator 1 (CAMTA1) [39] and the cAMP responsive element binding protein (CREB) 
together with the co-activator cAMP-regulated transcriptional co-activator 1  (CRTC1) [40].  
Interestingly, the expression of CAMTA1 is reduced in islets from the GK-rat [39].    
There are studies showing that expression and/or function of miRNAs can be modulated by other non-
coding RNAs. Indeed, the long non-coding RNA (lncRNA) ANRIL was reported to regulate miRNA 
networks [41]. The gene ANRIL is present in the CDKN2A/B genomic locus and variations at this gene 
locus are linked to increased risk of T2D.   ANRIL binds directly to the miRNAs acting as a miRNA 
“sponge” or through epigenetic regulation of miRNA transcription.  Two conserved miRNAs, miR-675-
3p and miR-675-5p, are directly generated from one of the exons of the lncRNA H19. These two 
miRNAs are expressed at very low level in adult islets and there is so far no evidence for a role in the 
control of fully mature β-cell functions [42]. However, H19 may affect β-cell expansion through 
repression of another miRNA, let-7 [42].  There is also emerging evidence indicating that circular RNAs 
(circRNAs), another recently discovered class of non-coding RNAs [43] modulate the activity of miRNAs. 
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Thus, the circRNAs ciRS7 and circHIPK3 were reported to sequester miR-7 and other islet miRNAs and 
to contribute to the regulation of β-cell functions [44, 45].     
Recent studies in human islets point to epigenetic regulation of gene expression as a factor 
contributing to impaired insulin secretion and to the development of T2D [46]. Studies in human islets 
showed high methylation of the DLK1-MEG3 cluster in T2D islets [21].  In addition, it was discovered 
that this region contains cell-specific histone modifications and a large number of miRNA genes. In all, 
the DLK1-MEG3 cluster contains 54 miRNAs of which miR-376 and miR-432 were demonstrated to 
control islet amyloid polypeptide (IAPP) level, which is involved in β-cell apoptosis.  Epigenetic 
regulation of miRNA expression was further demonstrated in a study investigating epigenetic 
differences between sexes in human islets. Differential methylation between sexes was associated 
with differences in the expression of miR-660 and miR-532 and related target genes [47]. 
The largest proportion of genetic variations associated with T2D is found in the islet of Langerhans 
[48].  Potentially, genetic variants within miRNA genes or their regulatory elements could result in 
differential expression of these small RNAs, favoring the development of T2D. However, there are 
currently only very few documented genetic variations at miRNA gene sites associated with T2D [49].  
One reason for current scarce knowledge regarding the genetic regulation of miRNA expression are 
coupled to the difficulty of precisely mapping promoters and transcription starting sites for miRNA 
genes.  This is a rather complex work and annotations are far from precise in this area, because miRNAs 
are generated from long primary transcripts that are rapidly cleaved by Drosha.  The transcription start 
sites are therefore located far from the mature miRNA and cannot be easily inferred from the genomic 
location of the mature miRNA [50].  
While many of the changes in miRNA level under physiological or pathological conditions are dictated 
by regulatory events occurring inside the β-cells, the miRNA profile can also be influenced by the 
delivery of miRNAs carried by exosomes released by other cells. Indeed, under insulin resistance 
conditions, exosomes released by skeletal muscles were shown to allow the delivery of miR-16 to β-
cells and to favour the expansion of the insulin-secreting cells [51]. On the other hand, the exosomes 
of lymphocytes invading the islets during the initial phases of Type 1 diabetes were found to transfer 
a subset of miRNAs, contributing to β-cell apoptosis [52]. An analogous mechanism may permit the 
exchange of miRNAs between β-cells and other cells present within the islets or with other metabolic 
tissues [53, 54].  
Environmental factors affecting miRNA expression 
Low physical activity and obesity are environmental risk factors for the development of T2D.   Obesity 
is associated with larger amounts of ectopic fat, and also the β-cells in human islets contain more fat-
droplets with increased BMI of the donor [55].  Both the rise in plasma levels of glucose and lipids 
affect β-cell function and the expression of many genes.  A summary of some of the miRNAs regulated 
by glucose and lipids are presented in Table 1. 
Glucose is a positive stimulator of insulin secretion in the short term (~1h), whereas long-term 
incubation of islets with high levels of glucose leads to glucotoxicity.  In studies performed in vitro, 24-
72h is enough to detect glucotoxicity.   The levels of several miRNAs are glucose-dependent including 
miR-375, miR-212/miR-132, and miR-130a [34, 56]. Incubation of Wistar rat islets for 1 h in increasing 
glucose concentrations raises the levels of miR-212 and reduces those of miR-130a [56].  As elevated 
levels of miR-130a diminish intracellular ATP [24], reduced expression of this miRNA might increase 
ATP during short term incubations, which is essential for enhanced insulin secretion.   
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More miRNAs are differentially-expressed after 24h incubation of Wistar rat islets in high glucose [56], 
showing that miRNAs may take part in β-cell adjustments under glucotoxic conditions.  As after 1h 
incubation, levels of miR-212/miR-132 increase while miR-130a expression decrease.  Interestingly, 
GK-rat islets (that are exposed to high blood glucose for an even longer period) display not only 
increased expression of miR-212/miR-132 but also higher levels of miR-130a. Thus, these observations 
suggest that the expression of miR-212/miR-132 is elevated due to increased glucose. The reasons of 
elevated levels of miR-130a in the islets of GK rats is hard to determine. They may be due to the genetic 
background of the GK-rat islets or to the fact that 24-h incubation in vitro is too short to mimic the 
glucotoxic effects occurring in vivo. Indeed, along this line, miR-130a was found to be elevated also in 
islets from human T2D donors [24].   
Glucose also indirectly influence the expression of some miRNAs. E.g. glucose-mediated regulation of 
thioredoxin-interacting protein (TXNIP) increases miR-204 expression [36] and glucose-regulated 
changes in AMPK activity reduce the levels of miR-184 [57]. Other changes in miRNA expression 
associated with glucose occur during weaning [58]. Experiments performed on rats show that when 
pups go from a fat-rich milk diet to a carbohydrate rich diet, the expression of  >60 miRNAs is modified.  
Many of these changes are prevented when maintaining the pups on a fat-rich diet, suggesting that 
these miRNAs are essential in achieving optimal glucose-regulated insulin secretion.  One of the 
clusters showing reduced expression after weaning is miR-17/miR-92. miR-17 targets 
Phosphofructokinase (Pfkp) and phosphatase with tensin homology (Pten) and knockdown of miR-17 
in an insulin-secreting cell line increases insulin secretion.  
Interestingly some of the miRNAs regulated by glucose are also differentially expressed after treatment 
of islets with palmitate to mimic lipotoxicity.  These include miR-132/miR-212 and miR-184.  Nesca et 
al showed that miR-132 expression is elevated by incubation with palmitate for 48 and 72h, whereas 
miR-184 expression decreases after the same treatment [37]. These miRNAs are also differentially  
expressed in mice given a high fat diet (HFD).   
Changes in islet miRNA levels associated with diabetes 
Several studies have investigated the changes in islet miRNA expression occurring in T2D models (Table 
1). Zhao et al. carried out a systematic analysis of the islet miRNA profile of obese ob/ob mice in 
diabetes resistant (B6) and diabetes prone (BTBR) backgrounds [59]. They identified several miRNAs 
that are differentially expressed between the two mice strains and are responsive to obesity. In 
particular, they observed a very strong decrease in the expression of miR-184 and the up-regulation of 
miR-132 and miR-212 in response to obesity [59]. They also found changes in the level of miR-34a, 
miR-146a and miR-152. Modifications in the expression of these and many other miRNAs, including 
miR-204 and miR-200 family members, were also detected in a global profiling of pancreatic islets from 
ob/ob mice [31, 59, 60], in prediabetic and diabetic db/db mice, lacking the leptin receptor [37], and 
in mice kept on a high fat diet [37]. Many of these changes are likely to be directly linked to obesity 
and to elevated free fatty acid levels. However, the up-regulation of miR-132, miR-212 and probably 
others may also be caused by prolonged hyperglycemia since it can be mimicked in vitro by exposing 
the islets to high glucose concentrations [37, 56] and is also observed in the islets of GK rats, a model 
of T2D that is not associated with obesity [56].  
The changes in islet miRNA expression detected under diabetic conditions may directly contribute to 
the development of the disease. However, some of them may be the consequence of the exposure of 
the cells to chronic hyperglycemia and hyperlipidemia and can even have positive impacts on β-cell 
functions. Indeed, while the alterations in the level of several miRNAs observed in the islets of diabetic 
animals have deleterious effects on β-cell activities [24, 31, 36, 37], the down-regulation of miR-184 
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promotes β-cell proliferation both in vitro and in vivo [37, 60]. Similar effects were also elicited by the 
up-regulation of miR-132 and were accompanied by an improvement in the secretory activity of 
pancreatic β-cells [37]. Thus, the changes in the expression of miR-184 and miR-132 are most probably 
part of an adaptive program allowing β-cells to release more insulin and to compensate for the 
diminished sensitivity of the target tissues. Another miRNA that appears to be involved in the 
adaptation of β-cells to insulin resistance is miR-7a. This miRNA is highly abundant in β-cells and 
regulates the expression of several key components necessary for insulin exocytosis [32]. The level of 
miR-7a in pancreatic islets is reduced under moderate insulin resistance conditions, resulting in 
improved insulin secretion. However, the expression of miR-7a raises progressively under severe 
diabetic conditions and can reach levels even higher than in healthy individuals, probably contributing 
to defective insulin release and to the progression of the disease [32].  
At present, only few studies investigated the potential changes in miRNA levels occurring in the islets 
of T2D patients.  As mentioned above, Kameswaran et al. identified a cluster of miRNAs in the DLK1-
MEG3 imprinted locus on chromosome 14q32 that is specifically expressed in human β-cells and is 
strongly downregulated in the islets of T2D organ donors [21]. The reduction of the level of these 
miRNAs was correlated to epigenetic changes and to the hypermethylation of the promoter 
sequences. Interestingly, the miRNAs belonging to the DLK1-MEG3 cluster were found to control the 
expression of genes involved in β-cell survival [21], suggesting that reduced levels of these miRNAs 
may contribute to T2D pathogenesis.  
Locke et al. used TaqMan arrays to perform a global profiling of islet miRNAs in cohorts of individuals 
with and without T2D [61]. These authors did not observe significant differences in the level of the 
miRNAs generated from the DLK1-MEG3 cluster. However, they detected in the islets obtained from 
T2D donors a dramatic increase of miR-187, a miRNA that was also very strongly up-regulated in the 
analysis carried out by Kameswaran et al. [21]. Interestingly, the level of miR-187 in human islets was 
found to be inversely correlated to insulin secretion. Moreover, overexpression of miR-187 in rat islets 
resulted in a drastic reduction of glucose-induced insulin release [61]. The mechanisms underlying the 
effect of miR-187 on insulin secretion remain to be precisely defined. However, part of the action may 
be exerted by modulating the expression of HIPK3 (homeodomain-interacting protein kinase 3), a 
protein kinase which is required for normal insulin secretion [62] and is a direct target of this miRNA 
[61].    
Few other studies reported changes in the level of specific miRNAs in the islets of T2D patients. 
Bomelson et al. investigated the expression of 8 miRNAs (miR-21, miR-122, miR-127-3p, miR-184, miR-
195, miR-375, miR-492 and miR-493*) in the islets of healthy and glucose intolerant individuals [63]. 
They found a significant increase in miR-21 in the islets of glucose-intolerant individuals and a tendency 
for a rise of miR-127-3p and miR-375. In contrast, Sebastiani et al. assessed the expression of miR-124a 
and observed higher levels of this miRNA in the islets of T2D patients but no significant differences in 
the expression of miR-375 [25].  Tattitoka et al. reported a decrease in miR-184 expression in the islets 
of T2D patients, reminiscent of the changes observed by different groups in animal models of T2D [60]. 
Finally, Ofori et al reported elevated expression of miR-130a, miR-130b and miR-152 in human islets 
of T2D patients [24].  Expression of these three miRNAs in human islets was highly correlated. Elevation 
of the expression of each of these miRNAs reduced the level of the common target Pyruvate 
Dehydrogenase E1 Alpha 1 Subunit (PDHA1), thereby reducing intracellular ATP and insulin secretion.   
 
As described above, the analysis of the islet miRnome revealed changes in many miRNAs occurring in 
conjunction with T2D development. However, only few of them were consistently observed. In animal 
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models, this is most probably explained by differences in the severity and in the progression of the 
disease. In fact, the level of some miRNAs is already modified in response to moderate insulin 
resistance while other miRNAs display altered expression only under severe pathophysiological 
conditions. Moreover, miR-7a and miR-200 family members show even opposite expression changes 
during the compensatory phases preceding the appearance of diabetes and after the disease is fully 
established, potentially leading to contradictory conclusions. Experiments performed with islets of 
human T2D donors are facing obstacles that are even more difficult to overcome. In fact, in contrast 
to rodent models, the number of available samples is usually very limited and, consequently, many 
confounding factors including the genetic background of the donors, the type of treatment, the quality 
of the glycemic control, the duration of the disease etc. cannot be controlled, inevitably resulting in a 
high variability of the data.  Added to this, the analysis of the miRnome struggle with technical 
variabilities between laboratories such as the use of different platforms and strategies for 
normalization of derived data. Currently, islet gene expression platforms are set-up to try to merge 
results from different islet preparations (e.g. TIGER data portal, https://www.t2dsystems.eu/tiger-
database).  In the near future, also miRNA expression data should be added to such a system.  
miRNAs as potential therapeutic targets for T2D 
As described above, T2D is associated with numerous changes in the islet miRNA profile. Thus, 
strategies permitting to correct the level of selected miRNAs could potentially allow to prevent or even 
treat the disease. Indeed, knockout mice lacking miR-200 family members were found to be resistant 
to streptozotocin-induced diabetes [31]. Moreover, the absence of this family of miRNAs permitted to 
prevent the development of a severe form of diabetes in Akita mice [31]. It is an exciting time for 
miRNA therapeutics and several miRNA drug candidates are in phase 1 and phase 2 clinical trials. This 
include e.g.  a phase 1 study with a Looked Nucleic Acid (LNA) based drug to inhibit miR-92 for future 
potential in wound healing and a phase 2 trial for miR-155 for patients with a specific form of T-cell 
lymphoma [64]. However, so far only very few studies attempted to treat T2D in animal models using 
strategies that could be potentially translated to humans.  Song et al. observed a decrease in miR-26a 
level in the islets of db/db mice and of mice kept on a high fat diet for 6 months [65]. They found that 
the injection of an adeno-associated virus (AAV8) construct allowing the overexpression of this miRNA 
is sufficient to prevent the rise in fasting blood glucose levels normally observed in high-fat diet fed 
mice [65]. This effect was linked to improved β-cell function and was attributed to the reduction of the 
expression of PTEN. Unfortunately, the manuscript does not include any description of the AAV8 
construct and it is unclear whether the expression of the miRNA was driven by a β-cell specific 
promoter.  
Mulder et al. used a different approach to treat high-fat diet fed mice. In this case, the authors 
generated an AAV8 construct that enables the overexpression of miR-132 [66], a miRNA with a 
beneficial impact on β-cell function and that is normally involved in the adaptation of β-cells to insulin 
resistance (see above). The expression of the construct was under the control of the rat insulin 
promoter and was therefore restricted to β-cells [66]. Interestingly, overexpression of miR-132 did not 
affect glucose homeostasis in mice kept on regular chow diet but enhanced insulin secretion and 
increased β-cell proliferation in mice on high-fat diet, resulting in improved blood glucose control [66].  
In a more recent study, Bijirk et al. investigated the effect of in vivo injection of cholesterol-conjugated 
antagomirs targeting miR-132 on islet function in mice [67]. It was verified that miR-132 expression 
was reduced in the islets, and the treatment resulted in a rise in insulin release and a decrease in blood 
glucose levels.  The discrepancy with previous studies might be due to dose and species differences or 
to effects exerted on other tissues that indirectly affect the activity of β-cells. However, this study 
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provides a proof of concept that antagomirs might hold a therapeutic potential, especially if coupled 
with targeted Looked Nucleic Acid (LNA) molecules, which are more stable in blood [68].   
 
Concluding remarks and future perspectives 
During the last years, we have gathered large amount of information about the contribution of miRNAs 
in the control of β-cell function and about their involvement in the development of T2D. In the coming 
years, we will be able to capitalize on this knowledge to design innovative strategies for preventing 
and treating the disease.  We now know that key miRNAs regulate the secretory activity of β-cells 
and/or control the β-cell mass (Figure 1). Genetic and environmental factors involved in the 
pathogenesis of T2D influence the expression of these miRNAs. These changes can lead either to 
dysfunctional insulin secretion, as is the case for miR-130a/b and miR-152, or in compensatory 
adaptations in β-cell activities, as is the case for miR-184 and miR-212/miR-132. In view of this, it is 
possible to envisage both therapeutic strategies aiming at correcting the level of the miRNAs displaying 
a negative impact on β-cells or approaches promoting miRNA changes that facilitate the adaptation of 
β-cells to increased insulin demand. However, for diabetes treatment we urgently need better tools to 
target one or more miRNAs specifically in β-cells. Indeed, none of the miRNAs studied so far is 
exclusively expressed in insulin-secreting cells and without a precise delivery of the miRNA-targeting 
tools to β-cells, any of these therapeutic strategies will most likely cause unacceptable side effects.  
Another aspect concerning the miRNAs that is rapidly expanding and taking increasing importance is 
their use as biomarkers. Indeed, measurements of miRNAs in plasma/serum have proved to be useful 
tools for predicting the manifestation of T2D or its associated complications [5, 69]. In view of the 
exiguous number of β-cells, changes in their miRNA profile are unlikely to be reflected in sizeable 
modifications in plasma miRNA levels.  However, in the future this obstacle may be overcome by 
approaches permitting the selective isolation from blood samples of vesicles released by β-cells [70].  
Despite rapid progress, we are only beginning to appreciate the contribution of miRNAs to islet 
function and to T2D development. For a full understanding of their role in T2D, future work will 
necessitate building of large-scale miRNA-mRNA networks and a better definition of genetic and 
epigenetic miRNA interactions. Moreover, although so far research in this field has almost exclusively 
focused on β-cells, miRNAs are very likely to regulate the function of other islet cells [71] and may thus 
contribute to T2D through other, yet to be identified, mechanisms. This promises new exciting 
discoveries also for the coming years. 
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Table and Figure legends 
 
 
 
Table 1. Summary of key islet miRNAs differentially expressed in T2D.  The table describes changes 
in islet expression induced by nutrients, in diabetes animal models (HFD-treated mouse, ob/ob-mouse 
and db/db-mouse models, and the GK-rat model) and human islets from T2D donors.  Data are from 
references [24, 31, 32, 34, 36, 56-58, 60, 61, 67]. ↑: increased expression vs control; ↓:decreased 
expression vs control; −: not differentially expressed vs control. 
 
miRNA 
Glucose 
Cells/islets 
Palmitate 
Cells/islets 
HFD 
mice 
ob/ob 
mice 
db/db 
mice 
GK 
rat 
Human 
T2D islets 
miR-7a/miR-7b   ↓ ↓ ↑ (adult) ↑(miR-7b) ↓ 
miR-130a/miR-130b ↓     ↑ ↑ 
miR-132/miR-212 ↑ ↑ ↑ ↑ ↑ ↑ ─ 
miR-338   ↓  ↓ ─  
miR-152 ↓   ↑  ↑ ↑ 
miR-184 ↓ ↓ ↓ ↓ ↓ ─ ↓ 
miR-187      ─ ↑ 
miR-200 family   ↓ ─ ↑ ─  
miR-204 ↑     ─  
miR-375 ↓ / ─  ↑ ↑  ─ ─ 
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Figure 1.  Summary of miRNA regulation of β-cell function and β-cell mass during development of 
T2D.  Genetic and environmental factors influence the capacity to secrete enough insulin to cover the 
organism needs. Increased demand on the β-cell due to insulin resistance requires augmented 
secretion from individual cells and enhanced proliferation to enlarge the β-cell mass.  Failure to 
compensate for the increased demand results in T2D development.  The image describes how genetic 
and/or environmental factors (e.g. increased amount of nutrients) regulate specific miRNAs. Whereas 
changes in the expression of some miRNAs are part of the aetiology of T2D, others occur as a 
compensatory mechanism for insulin resistance.  Of the miRNAs listed in the image a majority controls 
both the function and the mass of β-cells. miR-7a, miR-130a/b, miR-152 and miR-184 are differentially 
expressed in islets of healthy and T2D donors.  Data in this image are from [24, 31, 32, 34, 36, 56-58, 
60, 61, 67]. 
